Aflibercept
Protein / enzyme biologic targets VEGFA via inhibition
Regulatory milestones approvals, filings & regulatory actions · 12 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | EYLEA HD | — | 2025-11-19 – 2026-04-02 | fda.gov ↗ |
| Label expansions (7) | US (FDA) | EYLEA | — | 2012-09-21 – 2023-02-08 | fda.gov ↗ |
| Label expansion | US (FDA) | ZALTRAP | — | 2015-09-17 | fda.gov ↗ |
| Approved | EU (EMA) | Eylea | — | 2012-11-21 | europa.eu ↗ |
| Approved | US (FDA) | EYLEA | — | 2011-11-18 | fda.gov ↗ |
Trials 274 · started per year
Also used as a comparator or background therapy in 168 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02457975 Background | Jun 2015 → Aug 2019 | diabetic retinopathy | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 112 trials | ||||||
| Phase 1 | NCT06817343 Background | Sep 2024 → Feb 2029 expected | wet macular degeneration | Exegenesis Bio | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06132035 Comparator | Dec 2023 → May 2025 overdue | wet macular degeneration | Caregen Co. Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT04919096 Comparator | Apr → Sep 2022 | wet macular degeneration | Clover Biopharmaceuticals AUS Pty | Withdrawn | No outcome recorded |
| Phase 1 | NCT04989699 Comparator | Jul 2021 → Feb 2023 | wet macular degeneration | Ocular Therapeutix, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05324592 Comparator | Feb → Sep 2021 | diabetic macular edema | Mabwell (Shanghai) Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04370379 Comparator | May 2020 → Apr 2021 | wet macular degeneration | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04058535 Comparator | Feb → Dec 2020 | wet macular degeneration | Alteogen, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03630315 Background | Feb 2019 → Jan 2024 | wet macular degeneration | Ocular Therapeutix, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03585556 Background | Sep 2018 → Jan 2020 | wet macular degeneration | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03249740 Comparator | Aug 2017 → Sep 2018 | wet macular degeneration | Graybug Vision | Completed | No outcome recorded |
| Phase 1 | NCT01997164 Background | Nov 2014 → Oct 2015 | diabetic macular edema, wet macular degeneration | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02591914 Background | Feb 2014 → May 2016 | wet macular degeneration | Retinal Consultants of Arizona | Completed | No outcome recorded |
| Phase 1/211 trials | ||||||
| Phase 1/2 | NCT06672536 Comparator | Nov 2024 → Sep 2026 expected | wet macular degeneration | Sinocelltech Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06850922 Background | Jun 2022 → May 2026 | diabetic macular edema | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT05197270 Comparator | Dec 2021 → Mar 2027 expected | wet macular degeneration | 4D Molecular Therapeutics | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05961007 Comparator | Nov 2021 → Oct 2023 | diabetic macular edema, wet macular degeneration | Innovent Biologics (Suzhou) Co. Ltd. | Suspended | No outcome recorded |
| Phase 1/2 | NCT04626128 Background | Dec 2020 → Oct 2022 | wet macular degeneration | Clearside Biomedical, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03397264 Background | Jan 2018 → Mar 2020 | diabetic macular edema | Opthea Limited | Completed | No outcome recorded |
| Phase 1/2 | NCT02976012 Comparator | Jun 2016 → Jun 2018 | proliferative diabetic retinopathy | Southeast Retina Center, Georgia | Unknown | No outcome recorded |
| Phase 1/2 | NCT02228304 Comparator | Sep 2014 → Apr 2016 | macular degeneration | Neurotech Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1/2 | NCT01988246 Comparator | Dec 2013 → Apr 2018 | diabetic retinopathy | Rishi Singh | Completed | No outcome recorded |
| Phase 1/2 | NCT01926977 Comparator | Sep 2013 → May 2014 | wet macular degeneration | Arshad Khanani | Completed | No outcome recorded |
| Phase 1/2 | NCT02118831 Comparator | Mar 2012 → Feb 2014 | age-related macular degeneration, diabetic macular edema, retinal vein occlusion | California Retina Consultants | Completed | No outcome recorded |
| Phase 240 trials | ||||||
| Phase 2 | NCT07557121 Comparator | Jul 2026 → Jun 2027 expected | wet macular degeneration | AiViva BioPharma, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07213570 Comparator | Oct 2025 → Oct 2026 expected | colorectal cancer | National Cancer Institute, Naples | Recruiting | No outcome recorded |
| Phase 2 | NCT07205887 Background | Sep 2025 → Jun 2028 expected | age-related macular degeneration, occlusion of tributary of retinal vein | EyeBiotech Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06942520 Comparator | Mar 2025 → Dec 2027 expected | diabetic macular edema | Sierra Eye Associates | Recruiting | No outcome recorded |
| Phase 2 | NCT06839339 Comparator | Feb 2025 → Sep 2026 expected | wet macular degeneration | Beijing Anlong Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06845163 Background | Feb 2025 → Mar 2026 overdue | diabetic macular edema | Alexandria University | Recruiting | No outcome recorded |
| Phase 2 | NCT06321302 Comparator | May 2024 → Mar 2027 expected | diabetic retinopathy | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06116890 Background | Jan 2024 → Aug 2026 overdue | wet macular degeneration | Kyowa Kirin, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06196840 Comparator | Jan 2024 → Jun 2025 overdue | wet macular degeneration | Innostellar Biotherapeutics Co.,Ltd | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06099184 Comparator | Jan → Oct 2024 | diabetic macular edema | EyePoint Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06116916 Background | Jan 2024 → Aug 2026 overdue | diabetic macular edema | Kyowa Kirin, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05930561 Comparator | Aug 2023 → Feb 2029 expected | diabetic macular edema | 4D Molecular Therapeutics | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05891548 Comparator | May 2023 → Aug 2024 | age-related macular degeneration | Clearside Biomedical, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05381948 Comparator | Jun 2022 → Nov 2023 | wet macular degeneration | EyePoint Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05403749 Comparator | Jun 2022 → May 2024 | wet macular degeneration | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05275205 Comparator | Mar 2022 → Feb 2023 | wet macular degeneration | Unity Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05063734 Comparator | Aug 2021 → Jun 2022 | diabetes mellitus, diabetic macular edema | Oxurion | Terminated | No outcome recorded |
| Phase 2 | NCT04820452 Comparator | Apr 2021 → Jan 2023 | wet macular degeneration | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04684394 Background | Dec 2020 → Jan 2022 | wet macular degeneration | Gemini Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04567550 Comparator | Nov 2020 → Jun 2026 overdue | diabetic macular edema | AbbVie | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04101877 Comparator | Sep 2020 → Oct 2026 expected | wet macular degeneration | Vastra Gotaland Region | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04527107 Comparator | Jul 2020 → Sep 2023 | diabetes mellitus, diabetic macular edema | Oxurion | Completed | No outcome recorded |
| Phase 2 | NCT04331730 Background | Jan 2020 → Aug 2021 | wet macular degeneration | Alkahest, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03953079 Comparator | Sep 2019 → Dec 2020 | wet macular degeneration | Graybug Vision | Completed | No outcome recorded |
| Phase 2 | NCT03374670 Background | Nov 2018 → Dec 2019 | — | Ophthotech Corporation | Withdrawn | No outcome recorded |
| Phase 2 | NCT03186326 Comparator | Apr 2018 → May 2022 | colorectal cancer | Federation Francophone de Cancerologie Digestive | Completed | No outcome recorded |
| Phase 2 | NCT03452527 Background | Mar 2018 → Apr 2019 | choroidal neovascularization, wet macular degeneration | Iconic Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03279289 Background | Oct 2017 → Feb 2023 | colorectal cancer | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Completed | No outcome recorded |
| Phase 2 | NCT03126786 Comparator | Jul 2017 → Apr 2018 | diabetic macular edema | Clearside Biomedical, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02586727 Comparator | Oct 2015 → Dec 2018 | radiation-induced disorder | Larkin Community Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02357342 Comparator | Apr 2015 → Jan 2017 | age-related macular degeneration | Maturi, Raj K., M.D., P.C. | Completed | No outcome recorded |
| Phase 2 | NCT02348359 Background | Mar 2015 → Dec 2017 | age related macular degeneration 10, wet macular degeneration | Tyrogenex | Terminated | No outcome recorded |
| Phase 2 | NCT02397954 Background | Mar → Oct 2015 | — | Ophthotech Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02303184 Background | Jan 2015 → Mar 2016 | macular retinal edema, retinal vein occlusion | Clearside Biomedical, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02363621 Comparator | Jan 2015 → Oct 2017 | diabetic macular edema | Arshad Khanani | Completed | No outcome recorded |
| Phase 2 | NCT02214628 Background | Jul 2014 → Dec 2016 | age-related macular degeneration | Ophthotech Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT01971190 Comparator | Oct 2013 → Apr 2015 | central serous chorioretinopathy | Asan Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01805297 Comparator | Mar 2013 → Feb 2014 | — | University of Oklahoma | Completed | No outcome recorded |
| Phase 2 | NCT01796964 Comparator | Mar → Oct 2013 | age-related macular degeneration | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT01747551 Comparator | Jan 2013 → Nov 2016 | esophageal cancer, gastric cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2/38 trials | ||||||
| Phase 2/3 | NCT07520318 Comparator | Apr 2026 → Feb 2029 expected | wet macular degeneration | Shenzhen Oculgen Biomedical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07496567 Comparator | Apr 2026 → Jul 2028 expected | choroidal neovascularization, wet macular degeneration | EyeBiotech Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07440225 Comparator | Mar 2026 → Jun 2028 expected | choroidal neovascularization, wet macular degeneration | EyeBiotech Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04429503 Comparator | Jun 2020 → May 2022 | diabetic macular edema, type 1 diabetes mellitus, type 2 diabetes mellitus | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/3 | NCT04049266 Comparator | Oct 2019 → Nov 2021 | wet macular degeneration | Kodiak Sciences Inc | Terminated | No outcome recorded |
| Phase 2/3 | NCT02858076 Comparator | Nov 2016 → Jan 2020 | proliferative diabetic retinopathy | Jaeb Center for Health Research | Completed | No outcome recorded |
| Phase 2/3 | NCT02296567 Comparator | Dec 2014 → Jul 2016 | age-related macular degeneration | East Florida Eye Institute | Unknown | No outcome recorded |
| Phase 2/3 | NCT02645734 Comparator | ? → Feb 2016 | diabetic macular edema | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 360 trials | ||||||
| Phase 3 | NCT07705607 Comparator | Sep 2026 → Nov 2028 expected | diabetic macular edema | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07705555 Comparator | Aug 2026 → Oct 2028 expected | diabetic retinopathy, macular retinal edema | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07614776 Comparator | May 2026 → Jul 2027 expected | wet macular degeneration | Amgen | Recruiting | No outcome recorded |
| Phase 3 | NCT07489131 Comparator | Apr 2026 → Jul 2027 expected | diabetic macular edema | Alvotech Swiss AG | Recruiting | No outcome recorded |
| Phase 3 | NCT07489586 Comparator | Mar → Dec 2026 expected | wet macular degeneration | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07449936 Comparator | Feb 2026 → Oct 2027 expected | diabetic macular edema | EyePoint Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07449923 Comparator | Feb 2026 → Oct 2027 expected | diabetic macular edema | EyePoint Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07317934 Comparator | Jan 2026 → Mar 2028 expected | wet macular degeneration | Innostellar Biotherapeutics Co.,Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT07064759 Comparator | Jul 2025 → Nov 2028 expected | wet macular degeneration | 4D Molecular Therapeutics | Recruiting | No outcome recorded |
| Phase 3 | NCT06470373 Comparator | Jul 2025 → Sep 2026 expected | wet macular degeneration | Rophibio, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06985706 Comparator | May 2025 → Nov 2028 expected | diabetic macular edema | Belfast Health and Social Care Trust | Recruiting | No outcome recorded |
| Phase 3 | NCT06864988 Comparator | Mar 2025 → Jun 2027 expected | wet macular degeneration | 4D Molecular Therapeutics | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05251636 Background | Mar 2025 → Sep 2026 expected | age-related macular degeneration, ocular vascular disorder | Salutaris Medical Devices, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06683742 Comparator | Nov 2024 → Oct 2026 expected | wet macular degeneration | EyePoint Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06668064 Comparator | Oct 2024 → Aug 2026 overdue | wet macular degeneration | EyePoint Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06556368 Comparator | Aug 2024 → Aug 2026 overdue | wet macular degeneration | Kodiak Sciences Inc | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05126966 Comparator | Dec 2023 → Jan 2025 | wet macular degeneration | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Phase 3 | NCT05972473 Comparator | Sep 2023 → Feb 2027 expected | wet macular degeneration | Innovent Biologics (Suzhou) Co. Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05885503 Comparator | Jun 2023 → Jun 2026 | diabetic macular edema | RemeGen Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05727397 Comparator | Mar 2023 → Nov 2025 | wet macular degeneration | RemeGen Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05324774 Comparator | Feb 2022 → Sep 2023 | diabetic macular edema | Mabwell (Shanghai) Bioscience Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05407636 Comparator | Jan 2022 → Oct 2026 expected | choroidal neovascularization, wet macular degeneration | AbbVie | Recruiting | No outcome recorded |
| Phase 3 | NCT04739306 Comparator | Jul 2021 → Oct 2022 | diabetic macular edema | Celltrion | Completed | No outcome recorded |
| Phase 3 | NCT04964089 Comparator | Jun 2021 → Mar 2023 | wet macular degeneration | Kodiak Sciences Inc | Completed | No outcome recorded |
| Phase 3 | NCT04864834 Comparator | May 2021 → Jul 2022 | wet macular degeneration | Sandoz | Completed | No outcome recorded |
| Phase 3 | NCT04740931 Comparator | Mar 2021 → Aug 2022 | central retinal vein occlusion, macular retinal edema, partial retinal vein occlusion | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT04740905 Comparator | Mar 2021 → Jul 2022 | macular retinal edema, occlusion of tributary of retinal vein | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT04079231 Comparator | Feb 2021 → Jan 2023 | diabetic macular edema | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT04572698 Comparator | Nov 2020 → Jun 2023 | wet macular degeneration | Luye Pharma Group Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04611152 Comparator | Sep 2020 → May 2023 | diabetic macular edema | Kodiak Sciences Inc | Terminated | No outcome recorded |
| Phase 3 | NCT04603937 Comparator | Sep 2020 → Apr 2023 | diabetic macular edema | Kodiak Sciences Inc | Terminated | No outcome recorded |
| Phase 3 | NCT04592419 Comparator | Sep 2020 → Jun 2022 | macular retinal edema, retinal vein occlusion | Kodiak Sciences Inc | Completed | No outcome recorded |
| Phase 3 | NCT04392479 Comparator | Sep 2020 → Jun 2023 | colorectal cancer, metastatic neoplasm | Hôpital Franco-Britannique-Fondation Cognacq-Jay | Unknown | No outcome recorded |
| Phase 3 | NCT04480463 Comparator | Aug 2020 → Sep 2022 | wet macular degeneration | Sam Chun Dang Pharm. Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04522167 Comparator | Jul 2020 → Jun 2022 | age-related macular degeneration | Bioeq GmbH | Completed | No outcome recorded |
| Phase 3 | NCT04270747 Comparator | Jun 2020 → Jul 2022 | wet macular degeneration | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT04047472 Comparator | Nov 2019 → Feb 2024 | wet macular degeneration | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT05587062 Comparator | Oct 2019 → Jul 2022 | age related macular degeneration 7 | Cinnagen | Completed | No outcome recorded |
| Phase 3 | NCT04005352 Comparator | Sep 2019 → Sep 2022 | age-related macular degeneration | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04058067 Comparator | Aug 2019 → Jan 2023 | diabetic macular edema | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03917472 Comparator | Jul 2019 → Mar 2021 | diabetic macular edema | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03810313 Comparator | Jul 2019 → Jul 2021 | central retinal vein occlusion | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT03802630 Comparator | Jul 2019 → Jul 2021 | occlusion of tributary of retinal vein | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT03823300 Comparator | Mar 2019 → Oct 2020 | wet macular degeneration | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT03823287 Comparator | Feb 2019 → Oct 2020 | wet macular degeneration | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT03630952 Comparator | Dec 2018 → Sep 2020 | wet macular degeneration | Chengdu Kanghong Biotech Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT03710564 Comparator | Oct 2018 → Dec 2020 | age-related macular degeneration | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT03622593 Comparator | Oct 2018 → Oct 2020 | diabetic macular edema | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT03577899 Comparator | Sep 2018 → Sep 2020 | wet macular degeneration | Chengdu Kanghong Biotech Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT03622580 Comparator | Sep 2018 → Oct 2020 | diabetic macular edema | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT03610646 Comparator | Aug 2018 → Nov 2020 | diabetic macular edema | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 3 | NCT03481660 Comparator | Jul 2018 → Jun 2020 | diabetic macular edema | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03481634 Comparator | Jul 2018 → Nov 2020 | diabetic macular edema | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03386474 Background | Jan → Sep 2018 | wet macular degeneration | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03172299 Comparator | Jun 2017 → Jan 2025 | ocular melanoma | Centre Hospitalier Universitaire de Nice | Completed | No outcome recorded |
| Phase 3 | NCT02980874 Background | Jan 2017 → Dec 2018 | macular retinal edema, retinal vein occlusion | Clearside Biomedical, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02434328 Comparator | Jul 2015 → Apr 2017 | choroidal neovascularization, wet macular degeneration | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT02307682 Comparator | Dec 2014 → Apr 2017 | choroidal neovascularization, wet macular degeneration | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT01969708 Comparator | Sep 2014 → Nov 2016 | central retinal vein occlusion | The Emmes Company, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01940887 Background | May 2014 → Jun 2017 | age-related macular degeneration | Ophthotech Corporation | Terminated | No outcome recorded |
| Phase 424 trials | ||||||
| Phase 4 | NCT05990829 Comparator | Oct 2023 → Oct 2024 | diabetic macular edema | Tianjin Medical University Eye Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05941715 Comparator | Jul 2023 → Sep 2024 | wet macular degeneration | Medical University of Graz | Completed | No outcome recorded |
| Phase 4 | NCT05710471 Comparator | Jul 2022 → Jul 2023 | age-related macular degeneration | The University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT05282420 Comparator | Feb 2021 → Apr 2022 | central retinal vein occlusion with macular edema | South Valley University | Unknown | No outcome recorded |
| Phase 4 | NCT04698850 Comparator | Jan 2021 → Jan 2023 | wet macular degeneration | Faculty Hospital Kralovske Vinohrady | Withdrawn | No outcome recorded |
| Phase 4 | NCT04469595 Comparator | Aug 2020 → Dec 2024 overdue | diabetic macular edema | Alimera Sciences | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04411693 Comparator | Apr 2020 → Jan 2024 | diabetic macular edema | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT03999125 Comparator | Jun 2019 → Jun 2021 | diabetic macular edema | Sudhalkar Eye Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03832179 Comparator | Nov 2018 → Sep 2023 | cataract, diabetic macular edema | Bay Area Retina Associates | Completed | No outcome recorded |
| Phase 4 | NCT03709745 Comparator | Oct 2018 → Oct 2021 | occlusion of tributary of retinal vein | St. Erik Eye Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04153253 Comparator | Mar 2018 → Jul 2019 | retinal vascular disorder | Al Hadi Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02432547 Background | Jun 2017 → May 2022 | diabetic retinopathy | University of Sydney | Completed | No outcome recorded |
| Phase 4 | NCT04087746 Comparator | Jan 2017 → Jan 2019 | diabetic macular edema | Minia University | Completed | No outcome recorded |
| Phase 4 | NCT02495181 Comparator | Nov 2015 → Aug 2017 | — | Association for Innovation and Biomedical Research on Light and Image | Completed | No outcome recorded |
| Phase 4 | NCT02581891 Comparator | Nov 2015 → Apr 2019 | macular degeneration | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT02646670 Comparator | Jul → Oct 2015 | retinal disorder | Instituto de Olhos de Goiania | Completed | No outcome recorded |
| Phase 4 | NCT02471651 Comparator | Jun 2015 → Oct 2018 | diabetic macular edema | California Retina Consultants | Completed | No outcome recorded |
| Phase 4 | NCT02392364 Comparator | Apr 2015 → Nov 2018 | cystoid macular edema, diabetic macular edema | California Retina Consultants | Completed | No outcome recorded |
| Phase 4 | NCT02321267 Background | Dec 2014 → Dec 2024 | macular degeneration | Kagawa University | Unknown | No outcome recorded |
| Phase 4 | NCT02274259 Comparator | Oct 2014 → Jun 2015 | central retinal vein occlusion | Anders Kvanta | Completed | No outcome recorded |
| Phase 4 | NCT02130024 Comparator | Apr 2014 → Nov 2017 | age-related macular degeneration | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01958918 Comparator | Oct 2013 → Nov 2016 | wet macular degeneration | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01871376 Comparator | May 2013 → Sep 2016 | perifoveal exudative vascular anomalous complex | Gregg T. Kokame, MD | Completed | No outcome recorded |
| Phase 4 | NCT01824225 Comparator | Mar 2013 → Mar 2014 | age-related macular degeneration | Nihon University | Completed | No outcome recorded |
| Phase not applicable12 trials | ||||||
| — | NCT06929507 Comparator | Mar 2025 → Mar 2026 overdue | diabetic macular edema, impaired renal function disease, wet macular degeneration | University Hospital, Alexandroupolis | Recruiting | No outcome recorded |
| — | NCT07096713 Comparator | Jan → Jun 2024 | — | Benha University | Completed | No outcome recorded |
| — | NCT04932980 Comparator | May 2022 → Jun 2027 expected | wet macular degeneration | Berner Augenklinik | Active not recruiting | No outcome recorded |
| — | NCT04793100 Background | Mar 2021 → Mar 2025 | central retinal vein occlusion | Fondation Ophtalmologique Adolphe de Rothschild | Completed | No outcome recorded |
| — | NCT03941587 Comparator | Feb 2021 → Jun 2024 | perifoveal exudative vascular anomalous complex | Singapore National Eye Centre | Completed | No outcome recorded |
| — | NCT04707027 Comparator | Nov 2020 → Nov 2022 | perifoveal exudative vascular anomalous complex | Chiang Mai University | Unknown | No outcome recorded |
| — | NCT04882956 Comparator | Aug 2020 → Dec 2021 | macular degeneration | Benha University | Unknown | No outcome recorded |
| — | NCT03651011 Comparator | Aug 2018 → Oct 2021 | macular retinal edema, occlusion of tributary of retinal vein | Odense University Hospital | Completed | No outcome recorded |
| — | NCT04014556 Comparator | Apr 2016 → Oct 2018 | diabetic macular edema | University of Alexandria | Completed | No outcome recorded |
| — | NCT02457026 Background | Jan 2016 → Jan 2018 | wet macular degeneration | Duke University | Withdrawn | No outcome recorded |
| — | NCT02590094 Comparator | Oct 2015 → Jan 2019 | diabetic retinopathy | Panhandle Eye Group, LLP | Completed | No outcome recorded |
| — | NCT02174211 Comparator | Jun 2014 → Nov 2020 | age-related macular degeneration | King's College Hospital NHS Trust | Completed | No outcome recorded |
Press releases naming this drug 54 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-02 | Regeneron Pharmaceuticals | EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) regeneron.com ↗ |
| 2026-02-02 | Regeneron Pharmaceuticals | EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases regeneron.com ↗ |
| 2025-11-19 | Regeneron Pharmaceuticals | EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications regeneron.com ↗ |
| 2025-08-20 | Regeneron Pharmaceuticals | EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension regeneron.com ↗ |
| 2025-04-28 | Regeneron Pharmaceuticals | EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease regeneron.com ↗ |
| 2025-04-18 | Regeneron Pharmaceuticals | Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application regeneron.com ↗ |
| 2025-04-17 | Regeneron Pharmaceuticals | EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications regeneron.com ↗ |
| 2025-02-08 | Regeneron Pharmaceuticals | Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals regeneron.com ↗ |
| 2025-02-08 | Regeneron Pharmaceuticals | EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting regeneron.com ↗ |
| 2025-01-13 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel tevapharm.com ↗ |
| 2025-01-13 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel tevapharm.com ↗ |
| 2024-12-17 | Regeneron Pharmaceuticals | EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion regeneron.com ↗ |
| 2024-10-18 | Regeneron Pharmaceuticals | Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema regeneron.com ↗ |
| 2024-09-11 | Regeneron Pharmaceuticals | EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile regeneron.com ↗ |
| 2024-04-29 | Regeneron Pharmaceuticals | EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases regeneron.com ↗ |
| 2024-03-08 | Regeneron Pharmaceuticals | EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet regeneron.com ↗ |
| 2023-11-01 | Regeneron Pharmaceuticals | EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema regeneron.com ↗ |
| 2023-10-05 | Regeneron Pharmaceuticals | EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA regeneron.com ↗ |
| 2023-08-18 | Regeneron Pharmaceuticals | EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) regeneron.com ↗ |
| 2023-08-15 | Novartis Pharmaceuticals | Sandoz announces positive results from Mylight Phase lll study for biosimilar aflibercept novartis.com ↗ |
| 2023-08-10 | Regeneron Pharmaceuticals | Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration regeneron.com ↗ |
| 2023-07-29 | Regeneron Pharmaceuticals | Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS regeneron.com ↗ |
| 2023-06-27 | Regeneron Pharmaceuticals | Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema regeneron.com ↗ |
| 2023-06-27 | Regeneron Pharmaceuticals | FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler regeneron.com ↗ |
| 2023-04-25 | Roche Global Development | New Vabysmo data suggest greater retinal drying versus aflibercept in nAMD and DME roche.com ↗ |
| 2023-04-17 | Regeneron Pharmaceuticals | Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases regeneron.com ↗ |
| 2023-02-23 | Regeneron Pharmaceuticals | Aflibercept 8 mg BLA for Treatment of Wet Age-Related Macular Degeneration and Diabetic Macular Edema Accepted for FDA Priority Review regeneron.com ↗ |
| 2023-02-08 | Regeneron Pharmaceuticals | EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA regeneron.com ↗ |
| 2022-11-04 | Regeneron Pharmaceuticals | Aflibercept 8 mg Late-breaking Data Presented at Retina Society in Diabetic Macular Edema and Wet Age-related Macular Degeneration regeneron.com ↗ |
| 2022-10-21 | Regeneron Pharmaceuticals | Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA® (aflibercept) Injection regeneron.com ↗ |
| 2022-10-12 | Regeneron Pharmaceuticals | EYLEA® (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority Review regeneron.com ↗ |
| 2022-09-30 | Regeneron Pharmaceuticals | Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO regeneron.com ↗ |
| 2022-09-08 | Regeneron Pharmaceuticals | Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals regeneron.com ↗ |
| 2022-06-29 | Regeneron Pharmaceuticals | EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review regeneron.com ↗ |
| 2022-02-11 | Regeneron Pharmaceuticals | Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting regeneron.com ↗ |
| 2021-08-24 | Regeneron Pharmaceuticals | Regeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular Degeneration regeneron.com ↗ |
| 2021-05-03 | Novartis Pharmaceuticals | Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine novartis.com ↗ |
| 2021-05-01 | Novartis Pharmaceuticals | Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept novartis.com ↗ |
| 2021-03-30 | Regeneron Pharmaceuticals | NIH-sponsored Trial Finds EYLEA® (aflibercept) Injection Reduced Vision-threatening Complications by 68% after Two Years in Diabetic Retinopathy Patients regeneron.com ↗ |
| 2020-09-14 | Novartis Pharmaceuticals | Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME) novartis.com ↗ |
| 2020-07-27 | Novartis Pharmaceuticals | New Novartis analysis shows wet AMD patients achieved sustained fluid control faster with Beovu® versus aflibercept novartis.com ↗ |
| 2020-02-08 | Regeneron Pharmaceuticals | EYLEA® (aflibercept) Injection Reduced Risk of Developing Vision-Threatening Events by 75% After Two Years in Patients with Diabetic Retinopathy regeneron.com ↗ |
| 2019-10-08 | Novartis Pharmaceuticals | Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept novartis.com ↗ |
| 2019-08-13 | Regeneron Pharmaceuticals | FDA Approves EYLEA® (aflibercept) Injection Prefilled Syringe regeneron.com ↗ |
| 2019-05-13 | Regeneron Pharmaceuticals | FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy regeneron.com ↗ |
| 2018-10-27 | Novartis Pharmaceuticals | Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD novartis.com ↗ |
| 2018-10-25 | Regeneron Pharmaceuticals | EYLEA® (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial regeneron.com ↗ |
| 2018-09-13 | Regeneron Pharmaceuticals | FDA to Review EYLEA® (aflibercept) Injection for the Treatment of Diabetic Retinopathy regeneron.com ↗ |
| 2018-08-17 | Regeneron Pharmaceuticals | FDA Approves EYLEA® (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration regeneron.com ↗ |
| 2018-08-13 | Regeneron Pharmaceuticals | Regeneron Provides Regulatory Update on EYLEA® (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration regeneron.com ↗ |
| 2018-03-19 | Regeneron Pharmaceuticals | EYLEA® (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial regeneron.com ↗ |
| 2017-12-11 | Regeneron Pharmaceuticals | Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA® (aflibercept) Injection for Patients with Wet AMD regeneron.com ↗ |
| 2017-11-27 | Regeneron Pharmaceuticals | Regeneron Provides Update on EYLEA® (aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program regeneron.com ↗ |
| 2017-11-10 | Novartis Pharmaceuticals | Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness novartis.com ↗ |
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 449 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aflibercept | “Threeintravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used...” NCT02457975 ↗380“PURPOSE: To determine the maximum tolerated dose or maximal administered dose and pharmacokinetic and safety profiles of s.c. administered vascular endothelial growth factor...” PMID 20028764 ↗ Dec 2009 “Vascular endothelial growth factor (VEGF) Trap (aflibercept) is an angiogenesis inhibitor comprising portions of the extracellular domains of human VEGF receptors 1 and 2 fused...” PMID 19949018 ↗ Nov 2009 “Randomised, double-masked trial to compare the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in patients with neovascular...” PMID 41494750 ↗ Jan 2026 “COLLIDE is a multi-center, open-label, 1:1 randomized study looking at the effects of aflibercept (AFL; 2.0mg) plus OZURDEX (DEX; 0.7mg) implant combination therapy versus DEX...” NCT03629210 ↗ “Efficacy of Intravitreal Aflibercept Monotherapy for Submacular Hemorrhage Secondary to Neovascular Age-Related Macular Degeneration: A Prospective Clinical Trial” NCT03169660 ↗ “Anti-VEGFs including ranibizumab and biosimilars, aflibercept, faricimab, and brolucizumab will be used, as per the standard of care at participating sites.” NCT06985706 ↗ “Objective: To compare efficacy and safety of MYL-1701P, an aflibercept biosimilar, with reference aflibercept (Eylea [Regeneron]) in DME.” PMID 39264599 ↗ Oct 2024 “Outcome of Brolucizumab-dbll and Aflibercept Intravitreal Injection in the Treatment of Age-related Macular Neovascular Degeneration” NCT04882956 ↗ “Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).” NCT01331681 ↗ “Aflibercept 2 mg (0.05 ml) will be administered by intravitreal injection every month for three consecutive months.” NCT06845163 ↗ “Combination treatment may include: 5FU/LFA, capecitabine, oxaliplatin, irinotecan, bevacizumab, aflibercept” NCT07213570 ↗ “Aflibercept has been found to improve visual acuity and reduce macular thickness in pivotal trials.” NCT06416241 ↗ “Intravitreal injections of anti-VEGF (Aflibercept 2 mg, 0.05 ml) at a fixed regimen for six months” NCT06391411 ↗ “intravitreal injection of Anti-VEGF Aflibercept (Eylea®; manufactured in the United States)” NCT05282420 ↗ “Aflibercept may stop the growth of cancer cells by blocking blood flow to the cancer.” NCT00601991 ↗ “intravitreal aflibercept for the treatment of center-involved diabetic macular edema” PMID 35422607 ↗ Apr 2022 “Arm 4 active comparator, aflibercept (2mg) as per US FDA Label, 50μL volume.” NCT07520318 ↗ “All patients will receive 2.0 mg intravitreal aflibercept injection.” NCT01495221 ↗ “This injection may be ranibizumab, bevacizumab, or aflibercept.” NCT02471651 ↗ “Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)” NCT02581891 ↗ “Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye)” NCT00527423 ↗ “intravitreal ziv-aflibercept (aflibercept) injection” NCT03712904 ↗ “avastin,bevacizumab, eylea, aflibercept,” NCT02357342 ↗ “EYLEA (aflibercept) Injection” NCT01512966 ↗ “Eylea® (Aflibercept)” NCT04522167 ↗ “Eylea® (Aflibercept)” NCT05155293 ↗ “Eylea (Aflibercept)” NCT04450329 ↗ “Aflibercept (Eylea)” NCT02348359 ↗ “Aflibercept (Eylea)” NCT03585556 ↗ “aflibercept (2mg)” NCT04626128 ↗ “aflibercept” NCT03630315 ↗ |
| Known as | AFL | “EYLEA® (AFL 2.0 mg intravitreal injections) is an anti-VEGF treatment.” NCT03629210 ↗ |
| Known as | AFLB | “Aflibercept (AFLB) 2 mg IVT” NCT06864988 ↗1“Aflibercept (AFLB) 2 mg IVT” NCT07064759 ↗ |
| Known as | Aflibercept (Eylea) | “Aflibercept (Eylea)” NCT06845163 ↗ |
| Known as | aflibercept HD | “Eylea HD (aflibercept HD)” NCT07489131 ↗ |
| Known as | Alflibercept | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03340610 ↗ |
| Known as | AVE0005 | “To determine the overall objective response rate (ORR) of AVE0005 (ziv-aflibercept, aflibercept, VEGF trap, ZALTRAP®) 4.0 mg/kg intravenously (IV) every 2 weeks in participants...” NCT00284141 ↗15“A Phase I Open-label Dose-escalation Study of Intravenous Aflibercept (AVE0005, VEGF Trap) in Combination With R-CHOP Administered Every 2 Weeks or Every 3 Weeks in Patients...” NCT00644124 ↗ “Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)” NCT00532155 ↗ “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)” NCT00574275 ↗ “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)” NCT00327171 ↗ “aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)” NCT00327444 ↗ “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)” NCT00396591 ↗ “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)” NCT00561470 ↗ “Drug: aflibercept (AVE0005)” NCT00545246 ↗ “aflibercept (AVE0005)” NCT00479076 ↗ “AVE0005 (aflibercept)” NCT00921661 ↗ “aflibercept (AVE0005)” NCT00876044 ↗ “Aflibercept (AVE0005)” NCT01148615 ↗ “AFLIBERCEPT AVE0005” NCT01571284 ↗ “Aflibercept AVE0005” NCT01930552 ↗ “Aflibercept AVE0005” NCT01955629 ↗ |
| Known as | BAY86-5321 | “The study treatment Aflibercept (also called BAY 86-5321) is a drug that blocks a protein called vascular endothelial growth factor (VEGF) which causes abnormal growth and...” NCT06591598 ↗25“Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).” NCT01331681 ↗ “The study treatment intravitreal aflibercept (also called BAY865321) is injected into the eye.” NCT05473715 ↗ “Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)” NCT01363440 ↗ “Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)” NCT02581891 ↗ “Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)” NCT01521559 ↗ “Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose” NCT05850520 ↗ “Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)” NCT00637377 ↗ “Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)” NCT01012973 ↗ “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” NCT02305238 ↗ “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” NCT05511038 ↗ “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” NCT01783886 ↗ “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” NCT02818998 ↗ “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” NCT01482910 ↗ “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” NCT02120950 ↗ “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” NCT02540954 ↗ “Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)” NCT02581995 ↗ “Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)” NCT04423718 ↗ “Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)” NCT06662994 ↗ “2 mg aflibercept (EYLEA, BAY 86-5321)” NCT06422507 ↗ “Aflibercept (Eylea, BAY 86-5321)” NCT02396316 ↗ “Aflibercept (EYLEA, BAY86-5321)” NCT03639675 ↗ “Eylea (Aflibercept, BAY86-5321)” NCT04015180 ↗ “Aflibercept (Eylea, BAY86-5321)” NCT02800642 ↗ “Eylea (Aflibercept, BAY86-5321)” NCT04004208 ↗ “VEGF Trap-Eye (BAY86-5321)” NCT01249664 ↗ |
| Known as | Eylea | “Threeintravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used...” NCT02457975 ↗87“A 24 Month Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF-BB Pegylated Aptamer) Regiment Administered in Combination With Avastin®, Eylea®, or Lucentis®) During the...” NCT02214628 ↗ “InCNV is treated at the moment with off-label anti-VEGF (Vascular Endothelial Growth Factor) therapy and could also benefit from aflibercept (EYLEA), a new anti-VEGF currently...” NCT02556229 ↗ “Each eye will receive three to five q4week loading anti-VEGF injections of aflibercept (2-mg, EYLEA®) after enrollment to complete the initial loading phase of 5 doses.” NCT06610747 ↗ “The purpose of this study is to compare the safety and efficacy of intravitreal Eylea injections at a set interval, versus a variable dosing schedule” NCT02392364 ↗ “The included patients received 5 loading doses of intravitreal Aflibercept (2.0 mg/0.05 mL) (Eylea; Bayer, Berlin, Germany) given monthly.” NCT03974425 ↗ “Subjects will receive monthly intravitreous injections of Avacincaptad Pegol in combination with Lucentis, Avastin or Eylea.” NCT02397954 ↗ “Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).” NCT01331681 ↗ “Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema” NCT02924987 ↗ “Biological: Aflibercept IVT * Commercially available Active Comparator * Other Names: Eylea” NCT06942520 ↗ “intravitreal injection of Anti-VEGF Aflibercept (Eylea®; manufactured in the United States)” NCT05282420 ↗ “Aflibercept (trade name: Eylea®/EYLEA®) is an anti-VEGF drug developed by Regeneron/Bayer.” NCT05324774 ↗ “could also benefit from aflibercept (EYLEA), a new anti-VEGF currently indicated in AMD.” NCT02573038 ↗ “2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month” NCT01971190 ↗ “Patient will receiver Eylea® (Aflibercept) intravitreal injection once in a month” NCT06132035 ↗ “2.0 mg/0.05 mL of aflibercept (Eylea) is injected into the vitreous cavity” NCT03804099 ↗ “A comparator drug, Eylea® (aflibercept), will also be used in this study.” NCT07520318 ↗ “Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)” NCT02320474 ↗ “EYLEA® (AFL 2.0 mg intravitreal injections) is an anti-VEGF treatment.” NCT03629210 ↗ “Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)” NCT01363440 ↗ “Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)” NCT01521559 ↗ “Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose” NCT05850520 ↗ “Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye)” NCT00527423 ↗ “Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)” NCT00637377 ↗ “Aflibercept 2 mg/0.05 mL (Eylea; Bayer, Berlin, Germany)” NCT04014556 ↗ “Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)” NCT01012973 ↗ “Eylea® (Aflibercept, 114.3 mg/mL, 8 mg Per 70 μL)” NCT07489586 ↗ “administration of anti-VEGF Aflibercept (Eylea)” NCT04932980 ↗ “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” NCT02818998 ↗ “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” NCT02305238 ↗ “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” NCT01783886 ↗ “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” NCT05511038 ↗ “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” NCT02120950 ↗ “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” NCT01482910 ↗ “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” NCT02540954 ↗ “Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)” NCT02581995 ↗ “Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)” NCT04423718 ↗ “a drug called aflibercept (also called EYLEA)” NCT01773954 ↗ “intravitreal injection of aflibercept (EYLEA)” NCT02257502 ↗ “EYLEA® (aflibercept) Injection 2 mg (0.05mL)” NCT06864988 ↗ “EYLEA® (aflibercept) Injection 2 mg (0.05mL)” NCT05275205 ↗ “EYLEA® (aflibercept) Injection 2 mg (0.05mL)” NCT07064759 ↗ “EYLEA® (aflibercept) Injection 2 mg (0.05mL)” NCT07557121 ↗ “EYLEA (Aflibercept) intravitreal injection” NCT01578720 ↗ “Drug: Aflibercept (BAY86-5321, Eylea)” NCT06591598 ↗ “2 mg aflibercept (EYLEA, BAY 86-5321)” NCT06422507 ↗ “Drug: Aflibercept Injection [Eylea]” NCT04288232 ↗ “Drug: Aflibercept Injection [Eylea]” NCT06330220 ↗ “Aflibercept (Eylea, BAY 86-5321)” NCT02396316 ↗ “Eylea (Aflibercept, BAY86-5321)” NCT04015180 ↗ “Aflibercept (EYLEA, BAY86-5321)” NCT03639675 ↗ “Aflibercept (Eylea, BAY86-5321)” NCT02800642 ↗ “Eylea (Aflibercept, BAY86-5321)” NCT04004208 ↗ “Aflibercept(BAY86-5321, Eylea)” NCT05473715 ↗ “Aflibercept (Eylea®) - US only” NCT06321302 ↗ “EYLEA (aflibercept) Injection” NCT01512966 ↗ “Aflibercept Injection [Eylea]” NCT03453281 ↗ “Aflibercept Injection [Eylea]” NCT03197480 ↗ “Aflibercept Injection [Eylea]” NCT03355638 ↗ “Aflibercept Injection [Eylea]” NCT03651011 ↗ “Aflibercept Injection [Eylea]” NCT06205979 ↗ “Aflibercept Injection [Eylea]” NCT04153253 ↗ “Aflibercept Injection [Eylea]” NCT02645266 ↗ “Aflibercept Injection [Eylea]” NCT03845049 ↗ “Aflibercept (Eylea®)” NCT02646670 ↗ “Aflibercept (Eylea)” NCT07301775 ↗ “Aflibercept (EYLEA)” NCT01918878 ↗ “Eylea®” NCT02418754 ↗ |
| Known as | EYLEA (aflibercept) Injection | “EYLEA® (aflibercept) Injection” NCT02713204 ↗ |
| Known as | Eylea HD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07489131 ↗ |
| Known as | Eylea is the brand name. | “Eylea is the brand name.” NCT02142296 ↗ |
| Known as | FYB203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06708637 ↗ |
| Known as | IAI | “The purpose of this study is to evaluate the safety and efficacy of intravitreal aflibercept injection (IAI) in patients with neovascular polypoidal choroidal vasculopathy.” NCT02092532 ↗3“Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)” NCT01521559 ↗ “Intravitreal Aflibercept Injection (IAI)” NCT02713204 ↗ “Intravitreal Aflibercept Injection (IAI)” NCT01722045 ↗ |
| Known as | IVT-AFL | “The VEGA trial assessed the efficacy and safety of intravitreal aflibercept (IVT-AFL) in patients with neovascular glaucoma in a 13-week, randomized, double-masked,...” PMID 33330958 ↗ Dec 20201“intravitreal aflibercept (IVT-AFL)” PMID 33556381 ↗ Feb 2021 |
| Known as | REGN3 | “Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)” NCT02712008 ↗1“Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks.” NCT02418754 ↗ |
| Known as | vascular endothelial growth factor (VEGF) Trap | “Aflibercept, also known as vascular endothelial growth factor (VEGF) Trap, is an angiogenesis inhibitor with a unique mechanism of action.” NCT02624726 ↗ |
| Known as | VEGF Trap | “Vascular endothelial growth factor (VEGF) Trap (aflibercept) is an angiogenesis inhibitor comprising portions of the extracellular domains of human VEGF receptors 1 and 2 fused...” PMID 19949018 ↗ Nov 20095“A Phase I Open-label Dose-escalation Study of Intravenous Aflibercept (AVE0005, VEGF Trap) in Combination With R-CHOP Administered Every 2 Weeks or Every 3 Weeks in Patients...” NCT00644124 ↗ “An Exploratory Study of the Safety, Tolerability and Biological Effect of a Single Intravitreal Administration of VEGF Trap in Patients With Diabetic Macular Edema” NCT00320814 ↗ “Aflibercept (VEGF Trap) Recombinant human protein, at 25 mg/ml Dose : 4 mg/Kg -Day 1, q2w Route of administration: Intravenous (60 min infusion)” NCT01802684 ↗ |
| Known as | VEGF Trap-Eye | “Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).” NCT01331681 ↗21“intravitreal aflibercept injection (VEGF Trap-Eye; Regeneron, Tarrytown, NY, and Bayer HealthCare, Berlin, Germany)” PMID 23084240 ↗ Oct 2012 “Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)” NCT02581891 ↗ “Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose” NCT05850520 ↗ “Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye)” NCT00527423 ↗ “Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)” NCT00637377 ↗ “Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)” NCT01012973 ↗ “VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI])” NCT01521559 ↗ “VEGF Trap-Eye (Intravitreal Aflibercept Injection)” NCT01722045 ↗ “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” NCT02305238 ↗ “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” NCT02818998 ↗ “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” NCT05511038 ↗ “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” NCT01783886 ↗ “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” NCT01482910 ↗ “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” NCT02120950 ↗ “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” NCT02540954 ↗ “Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)” NCT02581995 ↗ “Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)” NCT04423718 ↗ “Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)” NCT06662994 ↗ |
| Known as | ZALTRAP | “To determine the overall objective response rate (ORR) of AVE0005 (ziv-aflibercept, aflibercept, VEGF trap, ZALTRAP®) 4.0 mg/kg intravenously (IV) every 2 weeks in participants...” NCT00284141 ↗9“Ziv-aflibercept (Zaltrap, Regeneron) is a recombinant fusion protein that acts as a soluble decoy receptor” NCT02590094 ↗ “aflibercept(Zaltrap): 4 mg/kg IV infusion for over 1hr (Do not administer as an IV push or bolus)” NCT04810585 ↗ “Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)” NCT00532155 ↗ “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)” NCT00327171 ↗ “aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)” NCT00327444 ↗ “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)” NCT00396591 ↗ “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)” NCT00561470 ↗ “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)” NCT00574275 ↗ “Drug: Ziv-Aflibercept 25 MG/ML [Zaltrap]” NCT03423823 ↗ |
| Known as | Zhuochuming | “Aflibercept Intravitreal Injection (Zhuochuming®)” NCT07612904 ↗ |
| Known as | ziv-aflibercept | “To determine the overall objective response rate (ORR) of AVE0005 (ziv-aflibercept, aflibercept, VEGF trap, ZALTRAP®) 4.0 mg/kg intravenously (IV) every 2 weeks in participants...” NCT00284141 ↗48“The MTD and RPTD were: capecitabine 850 mg/m2, P.O. bid, days 1-14, and ziv-aflibercept 6 mg/kg I.V., day 1, of each 21-day cycle.” PMID 31675952 ↗ Nov 2019 “* Ziv-aflibercept: will be administered 4 mg/kg IV on Day 1 of each cycle, repeating every 14 days.” NCT02079220 ↗ “Patients receive a higher dose of ziv-aflibercept (VEGF Trap) IV over 1 hour on day 1.” NCT00357760 ↗ “Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)” NCT00532155 ↗ “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)” NCT00561470 ↗ “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)” NCT00574275 ↗ “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)” NCT00327171 ↗ “aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)” NCT00327444 ↗ “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)” NCT00396591 ↗ “In the US, the US proper name is "ziv-aflibercept".” NCT02085005 ↗ “aflibercept (ziv-aflibercept)” NCT01688960 ↗ “Intravitreal ziv-Aflibercept” NCT03660345 ↗ |
| Action | Inhibit | “Evaluate the ability of this drug to bind and inactivate circulating vascular endothelial growth factor (VEGF) in these patients.” NCT00036946 ↗ |
| Modality | Protein / enzyme biologic | “comprising portions of the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of human immunoglobulin G” PMID 19949018 ↗ Nov 2009 |
| Route | Subcutaneous | “aflibercept administered subcutaneously to patients with advanced solid tumors.” PMID 20028764 ↗ Dec 2009 |
| Target | VEGFA | “By binding to VEGF-A, aflibercept prevents activation of the native VEGF receptors, VEGFR-1 and VEGFR-2.” NCT02432547 ↗ |